GSK’s travel plans, or lack thereof
GlaxoSmithKline responds to an article in 1"The Pink Sheet" (April 3, 2006, p. 8) discussing international mergers. "The article quotes comments made by Clifford Kalb, VP of Life Sciences at Wood Mackenzie, speculating on future mergers expected in the pharmaceutical industry," GSK notes. "Among those comments, the article references Mr. Kalb as saying that GlaxoSmithKline's CEO 'recently visited the offices of New Jersey Governor Jon Corzine seeking a tax break to relocate the firm's headquarters.' Mr. Kalb's speculation is completely wrong. The company's CEO has not met with Governor Corzine, and GlaxoSmithKline has no intention of moving its headquarters from the UK to the U.S.," GSK says...
You may also be interested in...
Sanofi-Synthelabo's merger with Aventis may be the first in a trend towards the creation of national pharma companies that could include the formation of "Pharma Swiss," according to Wood Mackenzie VP-Life Sciences Clifford Kalb
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.
Acquiring Clarion Brands from Swander Pace, Bridges Consumer Healthcare adds portfolio of OTC and supplement brands for symptoms including tinnitus, urinary pain relief and excessive sweating.